OSR Holdings updates Vaximm, BCM Europe AG on exclusive licensing agreement.

OSR Holdings, Inc. has updated the non-binding term sheet between its subsidiary Vaximm AG and BCM Europe AG, shortening the exclusivity period from six months to three months. The parties expect to finalize a definitive agreement within three months, with financial terms remaining unchanged at $20 million upfront and $60 million in milestones. Vaximm's orally administered cancer immunotherapy platform, VXM01, is the focus of the deal.